- 1 Digital morphometry of tumor nuclei correlates to BAP-1 status, monosomy 3,
- 2 gene expression class and survival in uveal melanoma
- 3 Christina Herrspiegel<sup>1,2</sup>, Thonnie Rose O. See<sup>3</sup>, Pia R. Mendoza<sup>4</sup>, Hans E.
- 4 Grossniklaus<sup>3</sup>, and Gustav Stålhammar<sup>\*1,2</sup>
- <sup>1</sup>St. Erik Eye Hospital, Stockholm, Sweden
- <sup>2</sup>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, and
- <sup>3</sup>Departments of Ophthalmology and Pathology, Emory University School of
- 8 Medicine, Atlanta, Georgia, USA.
- <sup>4</sup>Department of Pathology and Laboratory Medicine, Emory University School of
- 10 Medicine, Atlanta, Georgia, USA.
- 12 \*Corresponding author

- 13 Gustav Stålhammar, M.D. Ph.D. FEBO
- Oncology and Pathology service, St. Erik Eye Hospital
- 15 Department of Clinical Neuroscience, Karolinska Institutet
- 16 Polhemsgatan 50, 112 82
- 17 Stockholm, Sweden
- 18 Email: gustav.stalhammar@ki.se
- 19 Phone: +46 8 672 30 00

## **ABSTRACT**

21

27

29

31

41

22 Cytologic features such as the shape and size of tumor cells can predict metastatic 23 death in uveal melanoma and other cancers but suffer from poor reproducibility. In 24 this study, we investigate the interobserver concordance of digital morphometry, and 25 correlate the results with BRCA associated protein-1 (BAP-1) expression and BAP-1 gene mutation status, monosomy 3, gene expression classifications and patient 26 survival in uveal melanoma. The average number of cells analyzed in each of 107 tumors, was 1957 (SD 349). Mean time consumption was less than 2.5 minutes per 28 tumor. Identical morphometric classification was obtained for ≥ 85 % of tumors in all 30 twelve evaluated morphometric variables (κ 0.70–0.93). The mean nucleus area, nucleus perimeter, nucleus max caliper and nucleus to cell area ratio were significantly greater in tumors with low BAP-1 expression and gene expression class 32 33 2. Patients had significantly shorter survival if their tumors had low BAP-1 (Log-34 Rank p=0.002), gene expression class 2 (p=0.004), long nucleus perimeters 35 (p=0.031), long nucleus max calipers (p=0.029) and high mean nucleus to cell area 36 ratios (p=0.041) as defined in a training cohort and then tested in a validation cohort. 37 In the validation cohort, long nucleus perimeters and long nucleus max calipers 38 correlated with monosomy 3 (Pearson Chi-Square p=0.006 and p=0.009, 39 respectively). Long nucleus perimeters also correlated with BAP-1 mutation 40 (p=0.017). We conclude that digital morphometry can be fast and highly reproducible, that for the first time, morphometry parameters can be objectively quantitated in 42 thousands of cells at a time in sub-um resolutions, and that variables describing the shape and size tumor nuclei correlate to BAP-1 status, monosomy 3, gene expression 43 44 class as well as patient survival.

## 1. Introduction

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Uveal melanoma is the most common primary intraocular malignancy in adults (Singh et al., 2014). Less than 5 % of patients have clinically detectable metastases at the time of diagnosis (Singh et al., 2014). At a later stage however, up to 45 % of patients will develop metastases even if the eye containing the tumor has been removed (Kujala, Mäkitie and Kivelä, 2003). Once macrometastases develop, there is no effective treatment and median patient survival is only 4-12 months (Carvajal et al., 2016; Augsburger, Corrêa and Shaikh, 2009). Several methods for prognostication are in clinical use. Tumor thickness, diameter, location in the eye and presence of distant metastases determine tumor stage (Kivelä et al., 2017; Arnljots et al., 2018). Loss of chromosome 3 has a high positive and negative predictive value for metastasis (Bornfeld et al., 1996). Commercial gene tests based on the expression of 12 classifier genes have been developed and show excellent prognostic utility in separation of class 1 tumors with low metastatic risk from class 2 tumors with high metastatic risk (Onken et al., 2012). Furthermore, we have previously shown the prognostic utility of manual (Szalai et al., 2018) and digital image analysis-based (Stålhammar et al., 2019a) determination of the level of nuclear BAP-1 (nBAP-1) expression. In 1931, Callender described six types of uveal melanoma based on cytologic features such as cell shape and the size of the nucleus (Callender, 1931). The original classification could accurately predict metastatic death, but suffered from substantial intra- and interobserver discordance (Gamel, McCurdy and McLean, 1992; Coleman et al., 1996). After several modifications, the morphological classification of uveal melanoma now rely on assessments of the proportion of epitheloid tumor cells

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

(McLean et al., 1983; Seddon et al., 1987). Examination of cytological features still require a high level of cytologic expertise and suffer from poor reproducibility (Gamel, McCurdy and McLean, 1992). Computer-assisted methods have therefore been proposed as a way of facilitating these assessments. In 1982, Gamel et al. found that 13 of 18 nuclear and nucleolar features correlated significantly with patient mortality when evaluated with a digitizer superimposed on microscopic images at a rate of 100 cells per hour (Gamel et al., 1982). Since then, computers have improved manyfold in terms of their computing power, cost and the number and scope of software applications and we can now analyze a dozen of variables or more in thousands of cells per minute on inexpensive off-the-shelf laptop computers (Stålhammar et al., 2018; Stålhammar et al., 2016). Consequently, we see an opportunity to analyze cell morphometry features with digital image analysis and compare these to other prognostic factors including nBAP-1 expression in uveal melanoma patients from one American and one European referral center. 2. Methods 2.1. Patients and Samples The study adhered to the tenets of the Declaration of Helsinki. Methods were carried out in accordance with the relevant guidelines and regulations. The protocol for collection of specimens and data from St. Erik Eye Hospital, Stockholm, Sweden was approved by the regional ethical review board in Stockholm, and the protocol for collection of specimens and data from Emory Eye Center, Atlanta, GA, USA by the Emory Institutional Review Board.

Patients in the training cohort (n=27) were identified in the archives of the Oncology and Pathology service, St. Erik Eye Hospital and L.F. Montgomery Ophthalmic Pathology Laboratory, Emory Eye Center. Inclusion criteria were: 1) Enucleation performed before December 2017, 2) Histologically proven uveal melanoma, 3) paraffin block available, 4) gene expression classification available, 5) clinicopathological data available, including tumor thickness, diameter, location, Tcategory and cell type, 6) follow-up data available, 7) sufficient tissue for BAP-1 immunohistochemistry. Exclusion criteria were: 1) Prior history of plaque brachytherapy, proton beam irradiation and/or transpupillary thermotherapy (TTT), and 3) tumor fully necrotic or fully hemorrhagic. 27 patients met the criteria. Our follow-up data was confirmed and further extended in telephone interviews with patients or relatives. Informed consent was obtained from all participants. In order to establish generalizable morphometry thresholds for prediction of prognosis, we also included patients from the Cancer Genome Atlas (TCGA), made available by the National Cancer Institute at the National Institutes of Health (n=80). These patients had undergone enucleation due to primary uveal melanoma from 2011 through 2013, without previous brachytherapy, proton beam irradiation or TTT. Digitally scanned diagnostic slides were downloaded along with data on overall survival from TCGA on which the thresholds established in the training cohort were tested. BAP-1 mutation and monosomy 3 status was downloaded from the supplemental information to the publication by Robertson et al. (Robertson et al., 2017). No protected health information was accessed or downloaded from TCGA.

2.2. Immunohistochemistry

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

The paraffin blocks were cut into 4 µm sections, pretreated in EDTA-buffer at pH 9.0 for 20 minutes and incubated with mouse monoclonal antibodies against BAP-1 (clone C-4, Santa Cruz Biotechnology, Dallas, Texas, USA) and a red chromogen, and finally counterstained with haematoxylin and rinsed with deionized water. The deparaffinization, pretreatment, primary staining, secondary staining and counterstaining steps were run in a Bond III automated IHC/ISH stainer (Leica, Wetzlar, Germany). Dilutions between 1:20 and 1:500 had been evaluated before selecting 1:40. 2.3. Digital image analysis After sectioning and staining, all glass slides were digitally scanned to the .ndpi file format at ×400, using identical digital scanners at both institutions (Nano Zoomer 2.0 HT, Hamamatsu Photonics K.K., Hamamatsu, Japan). The digital image analysis (DIA) software used was the QuPath Bioimage analysis v. 0.2.0 m4 (Bankhead et al., 2017). The software was run on a standard off-the-shelf laptop computer (Apple Inc. Cupertino, CA). For assessment of the level of nBAP-1 expression, one positive cell (red chromogen in nucleus) and one negative cell (haematoxylin but no red chromogen in nucleus) was calibrated in each digitally scanned tissue section. All other parameters were left at default in order to limit time consumption and maintain ease of use. Tumors were then screened under low magnification  $(40\times)$  and the area exhibiting the most intense nBAP-1 staining selected for grading. Nuclear immunoreactivity was evaluated at 200×, in a circular 0.5 mm-diameter region of interest (corresponding to the field of view in a light microscope with a 400× objective) by automatic

classification (positive cell detection). Based on previous publications, the nBAP-1 expression was classified as "high" if immunoreactivity was detected in >30 % of tumor cells within the region of interest, and "low" if it was detected in  $\leq 30$  % of tumor cells (Stålhammar et al., 2019a; Szalai et al., 2018; See et al., 2019). A workflow for morphometric analysis was then created, including the following steps for each tumor: A) Identification of all cells within the same circular 0.5 mm-diameter region of interest used for assessment of the level of nBAP-1 expression, using the software's cell detection function with the following settings: Background nucleus radius 8 μm, median filter radius 0 μm, sigma 1.5 μm, minimum nucleus area 7.5 μm<sup>2</sup>, maximum nucleus area 200 μm<sup>2</sup>, threshold 0.1, max background intensity 2 and cell expansion 5 μm. B) Measurement in each detected cell in each region of interest of the following 12 cell morphometric variables: 1) Nucleus area (µm<sup>2</sup>). 2) Nucleus perimeter (µm). 3) Nucleus circularity. 4) Nucleus max caliper (μm). 5) Nucleus min caliper (μm). 6) Nucleus eccentricity. 7) Cell area (µm²). 8) Cell perimeter (µm). 9) Cell circularity. 10) Cell max caliper. 11) Cell min caliper. 12) Nucleus to cell area ratio (figure 1). Tumor areas with intense inflammation, heavy pigmentation, bleeding, necrosis or poor fixation were avoided. nBAP-1 classification and morphometric analysis was performed blinded to all other patient data including outcome. For measurement of interobserver concordance, two human observers performed the digital morphometry (morphometric variable above or below median value) and nBAP-1 classification (high or low) independently and blinded to patient outcomes.

2.4. Gene expression classification

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

Tumor tissue samples were obtained from freshly enucleated eyes by fine needle aspiration. The contents of the needle hub were transferred into one of two RNAsefree cryovials. Using the same needle, extraction buffer from the second cryovial was aspirated and expelled into the first. This was then placed in a specimen bag, immediately frozen to -80° C and shipped on dry ice for gene expression classification based on 12 discriminating genes (HTR2B, ECM1, RAB31, CDH1, FXR1, LTA4H, EIF1B, ID2, ROBO1, LMCD1, SATB1, and MTUS1) and 3 control genes (MRPS21, *RBM23*, and *SAP130*) at a commercial laboratory (Castle Biosciences Inc. Friendswood, TX, USA). Expression levels of the gene products are used to categorize tumors as either class 1 with low metastatic risk, or class 2 with high metastatic risk (Onken et al., 2012). 2.5. Statistical methods Differences with a p<0.05 were considered significant, all p-values being two-sided. The deviation of all clinicopathological variables from normal distribution was statistically significant, when evaluated by the Shapiro–Wilk test (p<0.05). For statistical tests of these variables, we therefore used the Mann-Whitney U test, which does not assume normally distributed data. The deviation of all morphometric variables from normal distribution was however not statistically significant (p>0.05), why we used one-way ANOVA with Bonferroni correction for these. For comparisons of categorical variables, two-by-two tables and Fisher's exact test were used. For correlation to Cox Proportional Hazards for metastasis and Kaplan-Meier metastasis-free survival, patients were split into two groups based on 1) the median value of each morphometric variable, and 2) receiver operating characteristics (ROC)

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

in the training cohort, with equal emphasis on sensitivity and specificity for the development of metastasis. The thresholds established in the training cohort were then tested in the validation cohort, with Kaplan-Meier survival analysis and in two-bytwo tables for Pearson Chi-Square correlation with BAP-1 mutation and monosomy 3. In evaluation of interobserver concordance, the percentage of identically classified cases and Cohen's kappa statistics (κ) were computed (Cohen, 1960). Metastasis-free follow-up was defined as the time in months from enucleation to the last occasion patients without metastases was seen or in contact alive. All statistical analyses were performed using IBM SPSS statistics version 25 (Armonk, NY, USA). 3. Results 3.1. Descriptive statistics The mean age at enucleation of patients in our training cohort was 66 years (SD 15). Of 27 patients, 15 were men and 12 women. 25 tumors originated in the choroid and 2 in the ciliary body. The cell type was mixed in 18 patients, spindle in 5 and epitheloid in 4. Mean tumor thickness was 8.6 mm (SD 3.7) and mean diameter 15.8 mm (SD 4.8). 12 tumors were of gene expression class 2 and 15 of class 1a or 1b. 14 tumors had low nBAP-1 expression and 13 high. Mean metastasis-free follow-up time was 47 months (SD 76). The validation cohort had similar features (Table 1). The average number of cells analyzed in each tumor was 1957 (SD 349), which took an average of 74 seconds (SD 21) for nBAP-1 classification and 71 seconds (SD 17) for morphometric analysis, adding up to 145 seconds or nearly twoand-a-half minutes per tumor.

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

3.2. Interobserver concordance Identical nBAP-1 classification was obtained for 25 of 27 tumors (93 %) in the training cohort, yielding a Cohen's kappa statistic indicating almost perfect agreement  $(\kappa = 0.85).$ Identical morphometric classification (morphometric variable above/below median value) was obtained for  $\geq 85$  % of tumors in all 12 variables, yielding substantial or almost perfect agreement (κ 0.70–0.93, Table 2). 3.3. Morphometry versus nBAP-1 expression and gene expression class The mean nucleus area, nucleus perimeter, nucleus max caliper and nucleus to cell area ratio were significantly greater in tumors with low nBAP-1 expression. Nucleus circularity, nucleus min caliper, nucleus eccentricity and cell area, cell perimeter, cell circularity, cell max and min caliper were however not significantly different (Table 3a). Similarly, the nucleus to cell area ratio, but not the other morphometric variables, were significantly greater in tumors of gene expression class 2 (Table 3b). 3.4. Adjusted thresholds The mean nucleus area, nucleus perimeter, nucleus max caliper and nucleus to cell area ratio were analyzed with ROC, with equal emphasis on sensitivity and specificity for the development of metastasis. Mean nucleus area achieved an area under the curve (AUC) of 0.54 (sensitivity 67 %, specificity 50 %, p=0.76) at threshold 28 µm<sup>2</sup>; Mean nucleus perimeter achieved an AUC of 0.58 (sensitivity 67 %, specificity 56 %, p=0.50) at threshold 22 μm; Mean nucleus max caliper achieved an AUC of 0.61

(sensitivity 56 %, specificity 67 %, p=0.38) at threshold 8.2 µm; and mean nucleus to cell area ratio achieved an AUC of 0.69 (sensitivity 56 %, specificity 67 %, p asymptotic significance p=0.12) at threshold 0.32 (figure 2). 3.5. Regression analysis and survival In survival analysis, the thresholds defined in our training cohort was applied to morphometry measurements in the validation cohort. Kaplan-Meier overall survival was significantly shorter for patients with tumors that had long nucleus perimeters (Log-Rank p=0.031), long nucleus max calipers (Log-Rank p=0.029) and high mean nucleus to cell area ratios (Log-Rank p=0.041). Patients also had significantly shorter survival if their tumors had low nBAP-1 expression (Log-Rank p=0.002) or gene expression class 2 (Log-Rank p=0.004). The nucleus area was however not associated with shortened survival (Log-Rank p=0.266, figure 3). In univariate Cox proportional hazards analyses of nucleus area, nucleus perimeter, nucleus max caliper and nucleus to cell area ratio, all variables were individual predictors of metastasis. In multivariate analysis, nucleus perimeter and nucleus to cell area ratio retained their significance (Table 4). In two-by-two tables, long nucleus perimeters correlated with BAP-1 mutation and monosomy 3 (Pearson Chi-Square p=0.017 and p=0.006, respectively). Long nucleus max calipers correlated with monosomy 3 (p=0.009) but not with BAP-1 mutation (p=0.085). Nucleus area and nucleus to cell area ratio did not correlate with *BAP-1* mutation or monosomy 3 (p>0.21).

## 4. Discussion

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

In this study, we have shown that digital morphometry of uveal melanoma can be fast and highly reproducible, and that variables describing the size of the tumor cell nuclei correlate to gene expression class, BAP-1 status, monosomy 3 and patient survival. On the other hand, no variable describing the shape and size of the entire tumor cell correlated to the prognostic factors, indicating that for prognosis, the morphological characteristics of tumor nuclei are more important. The prognostic importance of cell morphology is by no means a novel discovery or limited to uveal melanoma. Deregulations in cell signaling leading to increases in cell size has been described as one of the hallmarks of cancer (Hanahan and Weinberg, 2011). However, such increases in cell size have been hard to measure until now and issues with reproducibility, time consumption and level of expertise required for reliable assessments have limited its utility both in research and clinic. Modern user-friendly digital image analysis techniques offer an attractive solution to these problems, and for the first time we can now objectively quantitate multiple morphometry parameters in thousands of cells at a time. In turn, changes to the size and shape of tumor cells are but a consequence of changes in the genotype, epigenetics and environmental factors. These changes can be tested with alternative methods, such as gene expression tests, next generation sequencing and chromosome analysis (Robertson et al., 2017; Onken et al., 2012). As found by Onken et al. the helix-loop-helix inhibitor ID2 suppress the epithelial phenotype associated with an enlarged nucleus (Onken et al., 2006). Loss of ID2 upregulates the epithelial adhesion molecule E-cadherin, which in turn promotes the anchorage-independent cell growth required for metastasis. Consequently, we regard

the morphometric characteristics investigated here as biomarkers, primarily for the cancer genotype.

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

Limitations of this study include a limited sample size. Substantial investments in digital scanning capacity is required before the method presented here can be used. The time consumption specified does not include preanalytical operations such as digital scanning and loading and unloading of glass slides. Small changes in the settings of the software's cell detection function will influence the results greatly and even though measurements are automatized and the interobserver concordance is almost perfect as shown here, the definition of representative regions of interest requires at least a basic experience in ophthalmic pathology. This may reduce the generalizability of our method, the number of potential users and its application in everyday clinical routine. Further, as only one region of interest per tumor is defined, intratumor heterogeneity is not taken into account. As we have shown previously, there is significant variation in tumor characteristics including nBAP-1 expression in different subregions of UM (Stålhammar et al., 2019b). Last, our sample is not representative of all patients with uveal melanoma. We have only investigated the feasibility of digital morphometry in enucleated specimens without previous plaque brachytherapy. A large proportion of patients with uveal melanoma undergo primary plaque brachytherapy or proton beam radiotherapy and may never require enucleation. It remains unclear if the digital morphometry characteristics of small uveal melanomas is different from the relatively large tumors investigated here. Accordingly, we encourage future studies to confirm these results in larger cohorts that includes smaller tumors.

308 **Funding** 309 This work was supported in part by Karolinska Institutet (Karolinska Institutets 310 stiftelsemedel för ögonforskning), the Swedish Society of Medicine (Cronqvists 311 stiftelse) and Stockholm County Council (Stockholms läns landsting). 312 313 Acknowledgement 314 The results published here are in part based upon data generated by the TCGA 315 Research Network: https://www.cancer.gov/tcga. 316 References 317 318 Arnljots, T. S., Al-Sharbaty, Z., Lardner, E., All-Eriksson, C., Seregard, S., Stålhammar, G. 2018., Tumour thickness, diameter, area or volume? The prognostic 319 320 significance of conventional versus digital image analysis-based size estimation 321 methods in uveal melanoma. Acta Ophthalmol, 965, 510-518. DOI: 322 10.1111/aos.13668 323 324 Augsburger, J. J., Corrêa, Z. M., Shaikh, A. H., 2009. Effectiveness of Treatments for 325 Metastatic Uveal Melanoma. Am J Ophthalmol, 1481, 119-127. DOI: 326 10.1016/j.ajo.2009.01.023 327 328 Bankhead, P., Loughrey, M., Fernández, J., Dombrowski, Y., McArt, D., Dunne, P., 329 McQuaid, S., Gray, R., Murray, L., Coleman, H., James, J., Salto-Tellez, M., Hamilton, P., 2017. QuPath: Open source software for digital pathology image 330 analysis. Sci Rep, 71, 16878-16878. DOI: 10.1038/s41598-017-17204-5 331 332 Bornfeld, N., Prescher, G., Becher, R., Hirche, H., Jöckel, K. H., Horsthemke, B., 333 334 1996. Prognostic implications of monosomy 3 in uveal melanoma. The Lancet, 3479010, 1222-1225. DOI: 10.1016/s0140-6736(96)90736-9 335 336 337 Callender, G., 1931. Malignant Melanotic tumors of the eye. A study of histologic 338 types in 111 cases. Trans. Am. Acad. Ophthalmol. Otolaryngol. 36, 131-142. 339 340 Carvajal, R. D., Schwartz, G. K., Tezel, T., Marr, B., Francis, J. H., Nathan, P. D., 341 2016. Metastatic disease from uveal melanoma: treatment options and future 342 prospects. Br J Ophthalmol, 101, 38-44. DOI: 10.1136/bjophthalmol-2016-309034 343

- Cohen, J., 1960. A Coefficient of Agreement for Nominal Scales. Educational and
- Psychological Measurement, 201, 37-46.
- Coleman, K., Baak, J. P. A., van Diest, P. J., Mullaney, J., 1996. Prognostic Value of
- Morphometric Features and the Callender Classification in Uveal Melanomas.
- Ophthalmol, 10310, 1634-1641. DOI: 10.1016/s0161-6420(96)30452-1
- Gamel, J. W., McCurdy, J. B. and McLean, I. W., 1992. A comparison of prognostic
- covariates for uveal melanoma. Invest Ophthalmol Vis Sci, 336, 1919-1922.
- Gamel, J. W., McLean, I. W., Greenberg, R. A., Zimmerman, L. E., Lichtenstein, S.
- J., 1982. Computerized histologic assessment of malignant potential: A method for
- determining the prognosis of uveal melanomas. Hum Pathol. 1310, 893-897. DOI:
- 357 10.1016/s0046-8177(82)80048-8
- Hanahan, D., Weinberg, R., 2011. Hallmarks of Cancer: The Next Generation. Cell,
- 360 1445, 646-674. DOI: <u>10.1016/j.cell.2011.02.013</u>
- Kivelä, T., Simpson, E. R., Grossniklaus, H. E., Jager, M. J., Singh, A. D., Caminal, J.
- 363 M., Pavlick, A. C., Kujala, E., Coupland, S. E., Finger, P. T., 2017. Uveal Melanoma.
- AJCC Cancer Staging Manual. 8 ed. Chicago: Springer, 805-817.
- Kujala, E., Mäkitie, T., Kivelä, T., 2003. Very long-term prognosis of patients with
- malignant uveal melanoma. Invest Ophthalmol Vis Sci, 4411, 4651-4659. DOI:
- 368 <u>10.1167/iovs.03-0538</u>
- McLean, I., Foster, W., Zimmerman, L., Gamel, J., 1983. Modifications of
- 371 Callender's classification of uveal melanoma at the Armed Forces Institute of
- 372 Pathology. Am J Ophthalmol, 96, 502-509. DOI: <u>10.1016/j.ajo.2018.08.025</u>
- Onken, M. D., Ehlers, J. P., Worley, L. A., Makita, J., Yokota, Y., Harbour, J. W.,
- 375 2006. Functional gene expression analysis uncovers phenotypic switch in aggressive
- 376 uveal melanomas. Cancer res, 669, 4602-4609. DOI: <u>10.1158/0008-5472.CAN-05-</u>
- 377 <u>4196</u>

350

353

358

361

365

369

373

378

- Onken, M. D., Worley, L. A., Char, D. H., Augsburger, J. J., Correa, Z. M.,
- Nudleman, E., Aaberg, T. M., Altaweel, M. M., Bardenstein, D. S., Finger, P. T.,
- Gallie, B. L., Harocopos, G. J., Hovland, P. G., McGowan, H. D., Milman, T.,
- Mruthyunjaya, P., Simpson, E. R., Smith, M. E., Wilson, D. J., Wirostko, W. J.,
- Harbour, J. W., 2012. Collaborative Ocular Oncology Group report number 1:
- prospective validation of a multi-gene prognostic assay in uveal melanoma.
- Ophthalmol, 1198, 1596-1603. DOI: 10.1016/j.ophtha.2012.02.017
- Robertson, A. G., Shih, J., Yau, C., Gibb, E. A., Oba, J., Mungall, K. L., Hess, J. M.,
- Uzunangelov, V., Walter, V., Danilova, L., Lichtenberg, T. M., Kucherlapati, M.,
- Kimes, P. K., Tang, M., Penson, A., Babur, O., Akbani, R., Bristow, C. A., Hoadley,
- K. A., Iype, L., Chang, M. T., Cherniack, A. D., Benz, C., Mills, G. B., Verhaak, R.
- 391 G. W., Griewank, K. G., Felau, I., Zenklusen, J. C., Gershenwald, J. E., Schoenfield,

- L., Lazar, A. J., Abdel-Rahman, M. H., Roman-Roman, S., Stern, M.-H., Cebulla, C.
- 393 M., Williams, M. D., Jager, M. J., Coupland, S. E., Esmaeli, B., Kandoth, C.,
- Woodman, S. E., 2017. Integrative Analysis Identifies Four Molecular and Clinical
- 395 Subsets in Uveal Melanoma. Cancer Cell, 322, 204-220. DOI:
- 396 <u>10.1016/j.ccell.2017.07.003</u>

402

406

410


415

420

424

429

- Seddon, J. M., Polivogianis, L., Hsieh, C.-C., Albert, D. M., Gamel, J. W.,
- 399 Gragoudas, E. S., 1987. Death From Uveal Melanoma: Number of Epithelioid Cells
- 400 and Inverse SD of Nucleolar Area as Prognostic Factors. Archives of Ophthalmol,
- 401 1056, 801-806. DOI: 10.1001/archopht.1987.01060060087039
- See, T. R. O., Stålhammar, G., Phillips, S. S., Grossniklaus, H. E., 2019. BAP1
- Immunoreactivity Correlates with Gene Expression Class in Uveal Melanoma. Ocul
- 405 Oncol Pathol, 1-9. DOI:10.1159/000502550)
- Singh, N., Bergman, L., Seregard, S., Singh, A. D., 2014. Epidemiologic Aspects, in:
- 408 Damato, B. and Singh, A.D. (Eds.) Clinical Ophthalmic oncology: Uveal tumors
- 409 Clinical Ophthalmic Oncology. 2 ed. Berlin, Heidelberg: Springer, pp. 75-87.
- Stålhammar, G., Fuentes Martinez, N., Lippert, M., Tobin, N. P., Mølholm, I., Kis, L.,
- 412 Rosin, G., Rantalainen, M., Pedersen, L., Bergh, J., Grunkin, M., Hartman, J., 2016.
- Digital image analysis outperforms manual biomarker assessment in breast cancer.
- 414 Mod pathol, 294, 318. DOI: <u>10.1038/modpathol.2016.34</u>
- 416 Stålhammar, G., Robertson, S., Wedlund, L., Lippert, M., R antalainen, M., Bergh, J.,
- 417 Hartman, J., 2018. Digital image analysis of Ki67 in hot spots is superior to both
- 418 manual Ki67 and mitotic counts in breast cancer. Histopathol, 726, 974-989. DOI:
- 419 10.1111/his.13452
- 421 Stålhammar, G., See, T. R. O., Phillips, S., Seregard, S., Grossniklaus, H. E., 2019a.
- 422 Digital Image Analysis of BAP-1 Accurately Predicts Uveal Melanoma Metastasis.
- 423 Translational vis sci & technol, 6, e11. DOI: 10.1167/tvst.8.3.11
- Stålhammar, G., See, T. R. O., Phillips, S. S., Grossniklaus, H. E., 2019b. Density of
- 426 PAS positive patterns in uveal melanoma: Correlation with vasculogenic mimicry,
- 427 gene expression class, BAP-1 expression, macrophage infiltration, and risk for
- 428 metastasis. Mol vis, 25, 502-516.
- 430 Szalai, E., Wells, J. R., Ward, L., Grossniklaus, H. E., 2018. Uveal Melanoma
- 431 Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.
- 432 Ophthalmol, 1252, 203-209. DOI: 10.1016/j.ophtha.2017.07.018
- 434 **Legends**



436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

Figure 1. Illustration of cell morphometric measurements. A) Calipers denotes the largest and smallest diameters of the nucleus and cell. Nucleus eccentricity is a measure of how much the nucleus deviates from a spherical shape, presented as a number between 0.00 and 1.00. A completely spherical nucleus has an eccentricity of 0.00, a nucleus with the shape of an elliptical 3D solid would have an eccentricity of 0.5, whereas a 3D conical distribution would have a value of 1.00. Circularity compares the perimeter of a shape to the area it contains and is calculated by four times  $\pi$  times the area divided by the perimeter squared. The circularity of a circle is 1.00, and less for less circular objects. The nucleus to cell area ratio is the area of the nucleus divided with the area of the entire cell. B) Example of the morphologic appearance of a tumor mainly composed of epitheloid cells. C) In this tumor, a circular 0.5 mm-diameter region of interest (corresponding to the field of view in a light microscope with a 400× objective) has been identified. Within the region of interest, each cell is automatically analyzed for the level of nBAP-1 expression and 12 morphometric variables. D) The results of the measurements can be presented as frequency distributions. In this example, the mean nucleus to cell area ratio of the cells measured in the region of interest was 0.32 (dotted line). E) and F) A tumor mainly composed of spindle-like cells is shown for comparison. G) This tumor had a

- slightly lower mean nucleus to cell area ratio of 0.28. Cell illustration by
- iStock.com/Vitalii Dumma, East Ukraine Volodymyr Dahl National University Scale
- 456 bars: 100 μm.

	Training cohort	Validation cohort
n =	27	80
Mean age at diagnosis, years (SD)	66 (15)	62 (14)
Sex, n (%)		
Female	15 (56)	35 (44)
Male	12 (44)	45 (56)
Primary tumor location, n (%)		
Choroid	25 (93)	75 (94)
Ciliary body	2 (7)	5 (6)
Iris	0 (0)	0 (0)
Cell type, n (%)		
Spindle	5 (19)	28 (35)
Epitheloid	4 (15)	12 (15)
Mixed	18 (67)	39 (49)
N/a		1 (1)
Mean tumor thickness, mm (SD)	8.6 (3.7)	N/a
Mean tumor diameter, mm (SD)	15.8 (4.8)	N/a
Previous brachytherapy or TTT, n (%)		
No	27 (100)	80 (100)
Yes	0 (0)	0 (0)
AJCC T-category, n (%)		
1	0 (0)	0 (0)
2	7 (26)	14 (18)
3	14 (52)	33 (41)
4	6 (22)	33 (41)
Gene expression class, n (%)		
1a	9 (33)	N/a
1b	6 (22)	N/a
2	12 (44)	N/a
DIA nBAP-1 classification, n (%)		

High	13 (48)	N/a	
Follow-up months, mean (SD)§	14 (52) 47 (76)	N/a 28 (19)	

- Table 1. Characteristics of patients and tumors included in this study. SD, standard
- deviation. N/a, not available. TTT, Transpupillary thermotherapy.

	Interobserver concordance (%)	Cohen's κ
Nucleus area	85	0.70
Nucleus perimeter	85	0.70
Nucleus circularity	96	0.93
Nucleus caliper, max	85	0.70
Nucleus caliper, min	89	0.78
Nucleus eccentricity	96	0.93
Cell area	85	0.70
Cell perimeter	85	0.70
Cell circularity	93	0.85
Cell caliper, max	85	0.70
Cell caliper, min	85	0.70
Nucleus to cell area ratio	96	0.93

- Table 2. Interobserver concordance and Cohen's kappa statistics in classification of
- each morphometric variable as above or below the median value.

	nBAP-1 high	nBAP-1 low	P
Nucleus area, μm <sup>2</sup> (SD)	24.31 (4.38)	28.34 (3.40)	0.013
Nucleus perimeter, μm (SD)	19.61 (1.78)	21.37 (1.28)	0.007
Nucleus circularity	0.76 (0.04)	0.75 (0.04)	0.406
Nucleus caliper, max μm (SD)	7.52 (0.65)	8.21 (0.58)	0.007

Nucleus caliper, min μm (SD)	4.43 (0.59)	4.67 (0.36)	0.202
Nucleus eccentricity (SD)	0.76 (0.03)	0.77 (0.04)	0.524
Cell area, µm <sup>2</sup> (SD)	88.50 (15.10)	94.58 (12.42)	0.263
Cell perimeter, µm (SD)	37.05 (3.26)	38.33 (2.53)	0.263
Cell circularity	0.77 (0.01)	0.77 (0.01)	0.704
Cell caliper, max µm (SD)	13.62 (1.22)	14.09 (0.97)	0.270
Cell caliper, min μm (SD)	9.00 (0.79)	9.29 (0.59)	0.298
Nucleus to cell area ratio	0.28 (0.03)	0.30 (0.02)	0.031

463 Table 3a.

- Average values and *P* defined by one-way ANOVA with Bonferroni correction of cell
- morphometric variables in tumors of high versus low nBAP-1 expression. SD,
- standard deviation.

	Gene expression class	Gene expression	P
	1a or 1b	class 2	
Nucleus area, μm <sup>2</sup> (SD)	26.13 (3.93)	28.52 (3.66)	0.149
Nucleus perimeter, μm (SD)	20.28 (3.91)	21.46 (1.42)	0.084
Nucleus circularity	0.77 (0.04)	0.75 (0.04)	0.253
Nucleus caliper, max μm (SD)	7.75 (0.57)	8.25 (0.65)	0.065
Nucleus caliper, min μm (SD)	4.61 (0.58)	4.67 (0.38)	0.769
Nucleus eccentricity (SD)	0.76 (0.03)	0.77 (0.04)	0.378
Cell area, μm <sup>2</sup> (SD)	94.32 (11.05)	94.47 (13.60)	0.977
Cell perimeter, µm (SD)	38.32 (2.25)	38.29 (2.80)	0.984
Cell circularity	0.77 (0.01)	0.77 (0.01)	0.713
Cell caliper, max μm (SD)	14.07 (0.79)	14.09 (1.10)	0.959
Cell caliper, min μm (SD)	9.33 (0.60)	9.27 (0.62)	0.807
Nucleus to cell area ratio	0.28 (0.03)	0.30 (0.02)	0.049

Table 3b.

Average values and and *P* defined by one-way ANOVA with Bonferroni correction of cell morphometric variables in tumors of gene expression class 1a or 1b versus 2. SD, standard deviation.




Figure 2. Receiver operating characteristics (ROC) of the mean nucleus area, mean nucleus perimeter, mean nucleus max caliper and mean nucleus to cell area ratio in the training cohort (n=27), with equal emphasis on sensitivity and specificity for the

development of metastasis. Mean nucleus area (blue line) achieved an area under the curve (AUC) of 0.54 (sensitivity 67 %, specificity 50 %, p=0.76) at threshold 28  $\mu$ m<sup>2</sup>; Mean nucleus perimeter (red line) achieved an AUC of 0.58 (sensitivity 67 %, specificity 56 %, p=0.50) at threshold 22  $\mu$ m; Mean nucleus max caliper (green line) achieved an AUC of 0.61 (sensitivity 56 %, specificity 67 %, p=0.38) at threshold 8.2  $\mu$ m; and mean nucleus to cell area ratio (orange line) achieved an AUC of 0.69 (sensitivity 56 %, specificity 67 %, p asymptotic significance p=0.12) at threshold 0.32.

	Regression coefficient, β (SE)	Wald statistic	P	Hazard coefficient, Exp(b) (95% CI)
Univariate Cox proportional hazards				
Nucleus area > 28 μm <sup>2</sup>	0.5 (0.4)	1.3	0.256	1.6 (0.7–3.8)
Nucleus perimeter > 22 μm	1.3 (0.5)	6.9	0.009	3.5 (1.4–9.0)
Nucleus caliper, max > 8.2 μm	1.0 (0.4)	5.0	0.025	2.7 (1.1–6.5)
Nucleus to cell area ratio > 0.32	0.9 (0.5)	4.3	0.039	2.6 (1.0–6.3)
Multivariate Cox proportional hazard	s			
Nucleus area $> 28 \mu m^2$	-0.8 (0.6)	1.7	0.188	0.5 (0.1–1.5)
Nucleus perimeter > 22 μm	2.1 (0.9)	5.6	0.018	7.8 (1.4–42.4)
Nucleus caliper, max > 8.2 μm	-0.4 (0.8)	0.3	0.608	0.6 (0.1–3.4)
Nucleus to cell area ratio > 0.32	1.0 (0.5)	4.2	0.041	2.8 (1.0–7.5)

<sup>487</sup> Table 4.

Univariate and multivariate Cox Proportional Hazards analysis of the association between metastasis-free survival and cell morphometric variables. SE, standard error.








Figure 3.


Kaplan-Meier curves, cumulative overall survival in the validation cohort (n=80). A) Patients with tumors with mean nucleus area < 28  $\mu$ m $^2$  (blue) versus > 28  $\mu$ m $^2$  (red, Log-Rank p=0.266). B) Patients with tumors with mean nucleus perimeter < 22  $\mu$ m (blue) versus > 22  $\mu$ m $^2$  (red, Log-Rank p=0.031). C) Patients with tumors with mean nucleus max caliper < 8.2  $\mu$ m (blue) versus > 8.2  $\mu$ m $^2$  (red, Log-Rank p=0.029). D) Patients with tumors with mean nucleus to cell area ratio < 0.32 (blue) versus > 0.32 (red, Log-Rank p=0.041). The thresholds were established in the training cohort.














	Training cohort	Validation cohort
n =	27	80
Mean age at diagnosis, years (SD)	66 (15)	62 (14)
Sex, n (%)		
Female	15 (56)	35 (44)
Male	12 (44)	45 (56)
Primary tumor location, n (%)		
Choroid	25 (93)	75 (94)
Ciliary body	2 (7)	5 (6)
Iris	0 (0)	0 (0)
Cell type, n (%)		
Spindle	5 (19)	28 (35)
Epitheloid	4 (15)	12 (15)
Mixed	18 (67)	39 (49)
N/a		1 (1)
Mean tumor thickness, mm (SD)	8.6 (3.7)	N/a
Mean tumor diameter, mm (SD)	15.8 (4.8)	N/a
Previous brachytherapy or TTT, n (%)		
No	27 (100)	80 (100)
Yes	0 (0)	0 (0)
AJCC T-category, n (%)		
1	0 (0)	0 (0)
2	7 (26)	14 (18)
3	14 (52)	33 (41)
4	6 (22)	33 (41)
Gene expression class, n (%)		
1a	9 (33)	N/a
1b	6 (22)	N/a
2	12 (44)	N/a
DIA nBAP-1 classification, n (%)		
High	13 (48)	N/a
Low	14 (52)	N/a
Follow-up months, mean $(SD)^\S$	47 (76)	28 (19)

	Interobserver concordance (%)	Cohen's κ
Nucleus area	85	0.70
Nucleus perimeter	85	0.70
Nucleus circularity	96	0.93
Nucleus caliper, max	85	0.70
Nucleus caliper, min	89	0.78
Nucleus eccentricity	96	0.93
Cell area	85	0.70
Cell perimeter	85	0.70
Cell circularity	93	0.85
Cell caliper, max	85	0.70
Cell caliper, min	85	0.70
Nucleus to cell area ratio	96	0.93

	nBAP-1 high	nBAP-1 low	P
Nucleus area, µm <sup>2</sup> (SD)	24.31 (4.38)	28.34 (3.40)	0.013
Nucleus perimeter, µm (SD)	19.61 (1.78)	21.37 (1.28)	0.007
Nucleus circularity	0.76 (0.04)	0.75 (0.04)	0.406
Nucleus caliper, max μm (SD)	7.52 (0.65)	8.21 (0.58)	0.007
Nucleus caliper, min μm (SD)	4.43 (0.59)	4.67 (0.36)	0.202
Nucleus eccentricity (SD)	0.76 (0.03)	0.77 (0.04)	0.524
Cell area, $\mu m^2$ (SD)	88.50 (15.10)	94.58 (12.42)	0.263
Cell perimeter, µm (SD)	37.05 (3.26)	38.33 (2.53)	0.263
Cell circularity	0.77 (0.01)	0.77 (0.01)	0.704
Cell caliper, max µm (SD)	13.62 (1.22)	14.09 (0.97)	0.270
Cell caliper, min µm (SD)	9.00 (0.79)	9.29 (0.59)	0.298
Nucleus to cell area ratio	0.28 (0.03)	0.30 (0.02)	0.031

	Gene expression class 1a	Gene expression class 2	P
	or 1b		
Nucleus area, μm <sup>2</sup> (SD)	26.13 (3.93)	28.52 (3.66)	0.149
Nucleus perimeter, µm (SD)	20.28 (3.91)	21.46 (1.42)	0.084
Nucleus circularity	0.77 (0.04)	0.75 (0.04)	0.253
Nucleus caliper, max μm (SD)	7.75 (0.57)	8.25 (0.65)	0.065
Nucleus caliper, min μm (SD)	4.61 (0.58)	4.67 (0.38)	0.769
Nucleus eccentricity (SD)	0.76 (0.03)	0.77 (0.04)	0.378
Cell area, µm <sup>2</sup> (SD)	94.32 (11.05)	94.47 (13.60)	0.977
Cell perimeter, µm (SD)	38.32 (2.25)	38.29 (2.80)	0.984
Cell circularity	0.77 (0.01)	0.77 (0.01)	0.713
Cell caliper, max µm (SD)	14.07 (0.79)	14.09 (1.10)	0.959
Cell caliper, min µm (SD)	9.33 (0.60)	9.27 (0.62)	0.807
Nucleus to cell area ratio	0.28 (0.03)	0.30 (0.02)	0.049

	Regression coefficient, β (SE)	Wald statistic	P	Hazard coefficient, Exp(b) (95% CI)
Univariate Cox proportional hazards				
Nucleus area > 28 μm <sup>2</sup>	0.5 (0.4)	1.3	0.256	1.6 (0.7–3.8)
Nucleus perimeter > 22 μm	1.3 (0.5)	6.9	0.009	3.5 (1.4–9.0)
Nucleus caliper, max > 8.2 μm	1.0 (0.4)	5.0	0.025	2.7 (1.1–6.5)
Nucleus to cell area ratio > 0.32	0.9 (0.5)	4.3	0.039	2.6 (1.0–6.3)
Multivariate Cox proportional hazard	$\mathbf{s}$			
Nucleus area > 28 μm <sup>2</sup>	-0.8 (0.6)	1.7	0.188	0.5 (0.1–1.5)
Nucleus perimeter > 22 μm	2.1 (0.9)	5.6	0.018	7.8 (1.4–42.4)
Nucleus caliper, max > 8.2 μm	-0.4 (0.8)	0.3	0.608	0.6 (0.1–3.4)
Nucleus to cell area ratio > 0.32	1.0 (0.5)	4.2	0.041	2.8 (1.0–7.5)